The likelihood a breast cancer will respond to antiestrogen therapy depends on the tumor content of immunoreactive or ligand-binding estrogen receptor (ER). To investigate the failure of many ER-positive breast cancers to respond to antiestrogen therapy, we examined by gel-shift assay the ability of tumor ER to bind its cognate estrogen response element (ERE). Analysis of 38 primary breast cancers showed that some tumors containing abundant immunoreactive ER failed to demonstrate DNA binding ER. In many other ERpositive tumors, the fraction of DNA binding ER was low and consisted primarily of truncated receptor forms, which on Western analysis were revealed to be 50 kD homodimers and 67-50 kD ER heterodimers. The use of protease inhibitors during tumor extraction and the demonstration of nuclear-localizing ER and ERE-binding COUP (chicken ovalbumin upstream promoter) protein in these tumors indicated that the truncated forms of ER were likely present in vivo. The presence of intact DNA binding ER correlated with higher tumor content of immunoreactive sex steroid receptors (ER and/or PR), standard predictors of tumor responsiveness to antiestrogen, suggesting that loss or truncation of DNA binding ER may be an important prognostic parameter accounting for some forms of clinical resistance to antiestrogen therapy. 
Introduction
Most patients with breast cancer are treated with either chemotherapy or antiestrogenic agents. The likelihood a breast tumor will respond to antiestrogen (e.g., tamoxifen) therapy depends on the tumor level of estrogen receptor (ER)' as measured by radioligand binding or immunochemical assay (1) (2) (3) . Progesterone receptor (PR) content is also determined because it provides some indication that the tumor ER is functional and capable of inducing synthesis of PR (4) , although examples of breast cancers that express PR independent of ER are well known (5, 6) . Unfortunately, 20-30% of ER+/PR+ tumors and up to 60-70% of ER+/PR-tumors fail to respond to antiestrogen therapy for reasons that are poorly understood (1) (2) (3) . Some studies suggest that these endocrine-resistant tumors contain dysfunctional ER (3-1 1) . Because the early identification ofsuch endocrine-resistant tumors would allow patients to be started on alternative forms of therapy, investigators have been trying to develop assays to detect dysfunctional ER (8-1 1). To date, however, these assays have been difficult to implement and have not identified specific enzymatic or structural defects correlating with the clinical prevalence ofendocrine-resistant ER+ breast cancers.
Current immunochemical and radioligand measurements of ER content are based on the integrity of the receptor protein's most COOH-terminal hinge and steroid recognition domains, without regard to structural or functional abnormalities that might exist within its more NH2-terminal regions including the highly conserved zinc-finger DNA binding domain (12) (13) (14) (15) (16) (17) (18) . As with other members of the nuclear receptor superfamily, ER regulation ofgene expression occurs by the binding ofligand-occupied 67 kD receptor dimers to a defined estrogen responsive element (ERE) usually located within the promoter region of each target gene (16) (17) (18) . Rare and heritable clinical disorders involving defective steroid receptors have been linked to genetic mutations in specific receptor domains (19) . Mutations resulting in altered amino acids in the ER ligand binding domain as well as transcriptional splicing errors causing deleted portions ofentire ER domains have also been reported in some human breast tumors and cell lines (20) (21) (22) . In addition to these primary genetic events, it is also possible that posttranslational receptor modifications occur in some tumors and lead to functionally disabled ER with intact COOH-terminal domains (23, 24) . The differential susceptability of specific ER domains to endoproteolytic cleavage has long been recognized and accounts for the ligand binding meroreceptors (3S) that are often isolated along with intact (4-8S) ER from estrogen responsive tissues (23) . In fact, a steroid-inducible protease activity has been found in normal reproductive tissues that produces NH2-terminally truncated nuclear-localizing ER (-50 kD), suggesting that there may be a physiological role for this form of posttranslational ER modification (25) (26) (27) . Endogenous cleavage of 67 kD ER and formation of an -50 kD nuclear receptor product appears to be associated with the progression to hormonally-independent breast tumors in some murine models, and this has led investigators to suggest that truncated DNA binding ER may compete for available target gene response elements, interfering with normal receptor regulated gene transcription (28) .
Gel-shift analysis provides a sensitive means of assaying relatively pure receptor proteins for high affinity, high specificity DNA binding function (29, 30) ; however, these assays have not yet been applied to the functional assessment of receptors from extracts of primary human tumors. We developed stringent assay conditions that eliminate most nonspecific DNA binding by proteins present in the high salt extracts of both primary breast tumor samples and cultured breast cancer cells. The DNA binding affinity and specificity of this assay was initially confirmed by comparing ER complexes formed with a synthetic 35-mer containing either the ERE consensus sequence (5'-GGTCACAGTGACC-3'), or a base substituted EREm sequence (5'-GGACACAGTGTCC-3') that preferentially binds progesterone, androgen, or glucocorticoid receptors (31) . Because thyroid hormone receptors (THR), retinoic acid receptors (RAR), ER, and the recently cloned transcriptional factor known as COUP (chicken ovalbumin upstream promoter) all possess near equivalent ERE binding affinity and specificity and may be found in human tissue samples (16-18, 32, 33) , antibodies to ER and COUP are presently used to confirm the identity of proteins found in the gel-shifted ERE complexes. Using this assay system to screen for DNA binding ER (ER-ERE) contained in primary breast tumor extracts, we now report on the high frequency of truncated DNA binding ER found in ER+/PR-breast tumors, as well as the fact that some tumors contain immunoreactive ER that appears unable to bind DNA or form ER-ERE complexes.
Methods
Whole-cell extracts were prepared for ER analysis using -100-200 mg of wet tumor weight or 10' cultured cells. For assay standardization, partially purified human ER was obtained from nuclei of transfected Chinese hamster ovary cells (CHO') (12) that were isolated by douncing freshly harvested cells in 0.25 M sucrose, pelleting twice through 1.7 M sucrose cushions, homogenizing in a nuclear lysis buffer, and extracting receptor by ammonium sulfate precipitation and dialysis (34) . Freshly excised tumors were carefully dissected before cryopreservation (< -800C); at the time ofanalysis these samples were pulverized to powder at liquid nitrogen temperature using a Bessman tissue pulverizer (Fisher Scientific Co., Pittsburgh, PA), placed into ice-cold extraction buffer (20 (35, 36) . Complexes were then electrophoretically separated on a 4% loosely cross-linked (acrylamide/bisacrylamide = 30:1) nondenaturing gel, using 0.5X TBE (50 mM Tris-50 mM boric acid-l mM EDTA) as a running buffer, and the gel was then dried and autoradiographed to reveal complexed or free bands. To identify the protein bound in the retarded complexes, 0.05 gg of antibody was added to the incubation mix to observe supershifting of the ERE bound complexes. Murine monoclonal antibodies to human ER (D75, H222, H226) were supplied by G. L. Greene (37) , and high titer rabbit anti-COUP antiserum was supplied by M.-J. Tsai (33) . The ERE binding specificity of the complexes was confirmed by substituting labeled mutant EREm sequences (shown below) to observe loss of the gel-retarded complexes. Synthetic duplexed and single-stranded DNA oligomers used for this procedure were: duplexed ERE:
5' GTCCAAAGTCAGGTCACAGTGACCTGATCAAAGTT 3'; duplexed EREm: 5' GTCCAAAGTCAGGACACAGTGTCCTGATCAAAGTT 3'; 1:1 mix of single-stranded 20-mers:
For Western blot analysis ofER containing tumor extracts, samples were boiled in SDS (1%) and DTT (100 mM), run on SDS-polyacrylamide gels (10%), membrane transferred (Immobilon-P; Millipore, Bedford, MA), and ER detected by hybridization with monoclonal antibody (H222) and secondary reaction to rabbit anti-rat IgG and 1251I-Protein A (100 ,gCi/,g; NEN DuPont, Wilmington; DE). In some studies the gel-shifted free and DNA bound receptor was membrane transferred in methanol-tris-glycine (20%, 25 mM, 192 mM; pH 8.3) buffer and detected by monoclonal antibody hybridization as a gelshift immunoblot assay.
Results and Discussion
Gel-shift analysis ofpurified 67 kD human ER, derived from a stably transfected CHO' expressing 2 106 ER molecules per cell (12) , produces a single gel-retarded band referred to as isoform a, as shown in Fig. 1 A. Coincubation ofthis purified ER with anti-ER monoclonals (H222, D75, H226) produces a supershift of isoform a, consistent with the increased size of the antibody bound ER-ERE complex. A more complex gel-shift pattern results from assay of whole-cell MCF-7 human breast cancer extracts containing 2 2 X 104 ER molecules per cell. These whole-cell ER extracts produced a much broader gelshifted band composed of ER-ERE isoform a (recognized by both D75 and H226) and abundant amounts of COUP-ERE complex (whose mobility is similar to the ER-ERE isoform b), recognized by the highly specific anti-COUP antibody. These studies indicated that gel-shift analysis could detect as little as 0.1 fmol of DNA bound ER from whole-cell extracts containing 50 ,ug of total protein including other ERE cross-reacting members of the steroid receptor superfamily (COUP, THR, RAR).
Many ER-positive breast tumors (e.g., extract E in Fig. 1 mors to endocrine therapy will not be known for many years because all ofthe primary tumors were diagnosed and resected within the past 3 yr. However, the significant association between loss of intact DNA binding ER and known predictors of tumor resistance to antiestrogen therapy (lower immunoreactive ER and lack ofPR) supports the possibility that measuring the fraction ofDNA binding ER may have important prognostic utility. It is provocative that the 67% prevalence of intact DNA binding ER found in those tumors with abundant PR and the 33% prevalence in tumors with minimal PR content are figures that match accepted antiestrogen response rates for these particular tumor subsets (1) . Because a physiologically inducible ER endoprotease activity has been identified in rodent reproductive tissues (25) (26) (27) , these gel-shift results detecting similarly truncated forms of ER in primary human breast tumors have encouraged further inquiry into posttranslational receptor modifying mechanisms associated with endocrine-resistant ER+ breast cancers. In preliminary studies using a nude-mouse model system to compare tamoxifen-resistant and tamoxifen-sensitive MCF-7 tumor growth, we have detected minor amounts of truncated (< 50 kD) ER associated with excess endoprotease activity in the tamoxifen-resistant, receptor-positive breast tumors (41) . With greater availability ofcyropreserved human breast tumors collected from patients whose clinical response to tamoxifen is known, the predictive value of truncated forms of DNA-binding ER can be more fully evaluated.
